- Markets
- Healthcare
- WINDLAS
WINDLAS
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Windlas Biotech Gets GMP Certification For New Injectable Facility
Jan 10 (Reuters) - Windlas Biotech Ltd WINL.NS:
RECEIVES GMP CERTIFICATION FOR NEW INJECTABLE FACILITY
Source text: ID:nBSE7wPY4V
Further company coverage: WINL.NS
(([email protected];;))
Jan 10 (Reuters) - Windlas Biotech Ltd WINL.NS:
RECEIVES GMP CERTIFICATION FOR NEW INJECTABLE FACILITY
Source text: ID:nBSE7wPY4V
Further company coverage: WINL.NS
(([email protected];;))
Windlas Biotech June-Quarter Consol Net Profit 134.8 Mln Rupees
Aug 13 (Reuters) - Windlas Biotech Ltd WINL.NS:
JUNE-QUARTER CONSOL NET PROFIT 134.8 MILLION RUPEES
JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 1.75 BILLION RUPEES
Source text for Eikon: ID:nBSE9tJKW
Further company coverage: WINL.NS
(Reporting by VijayDattaram Malkar)
(([email protected];))
Aug 13 (Reuters) - Windlas Biotech Ltd WINL.NS:
JUNE-QUARTER CONSOL NET PROFIT 134.8 MILLION RUPEES
JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 1.75 BILLION RUPEES
Source text for Eikon: ID:nBSE9tJKW
Further company coverage: WINL.NS
(Reporting by VijayDattaram Malkar)
(([email protected];))
India's Windlas Biotech hits record high on Q4 profit jump
** Shares of Windlas Biotech WINL.NS up as much as 17.2% to a record high of 648 rupees
** The pharmaceutical products manufacturer reported a 48.5% Y/Y rise in its consolidated net profit on Monday
** Revenue from operations rose 21.7%
** EBITDA margin expands to 12.8% from 11.7% a year earlier
** WINL on track for a second straight session of gains, if trends hold
** More than 442,000 shares traded by 10:05 a.m. IST, 8.8x its 30-day avg; busiest day yet since March 1s
** Including session's move, stock is up 44.2% YTD
($1 = 83.3275 Indian rupees)
(Reporting by Navamya Ganesh Acharya in Bengaluru)
(([email protected]; +91 8805175330 ;))
** Shares of Windlas Biotech WINL.NS up as much as 17.2% to a record high of 648 rupees
** The pharmaceutical products manufacturer reported a 48.5% Y/Y rise in its consolidated net profit on Monday
** Revenue from operations rose 21.7%
** EBITDA margin expands to 12.8% from 11.7% a year earlier
** WINL on track for a second straight session of gains, if trends hold
** More than 442,000 shares traded by 10:05 a.m. IST, 8.8x its 30-day avg; busiest day yet since March 1s
** Including session's move, stock is up 44.2% YTD
($1 = 83.3275 Indian rupees)
(Reporting by Navamya Ganesh Acharya in Bengaluru)
(([email protected]; +91 8805175330 ;))
Windlas Biotech Consol Net Profit Rises
May 20 (Reuters) - Windlas Biotech Ltd WINL.NS:
WINDLAS BIOTECH LTD - DIVIDEND 5.5 RUPEESPER SHARE
WINDLAS BIOTECH LTD MARCH-QUARTER CONSOL NET PROFIT 169.9 MILLION RUPEES VERSUS 114.4 MILLION RUPEES
WINDLAS BIOTECH LTD MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 1.71 BILLION RUPEES VERSUS 1.41 BILLION RUPEES
Source text for Eikon: ID:nNSE8rxDRK
Further company coverage: WINL.NS
(([email protected];))
May 20 (Reuters) - Windlas Biotech Ltd WINL.NS:
WINDLAS BIOTECH LTD - DIVIDEND 5.5 RUPEESPER SHARE
WINDLAS BIOTECH LTD MARCH-QUARTER CONSOL NET PROFIT 169.9 MILLION RUPEES VERSUS 114.4 MILLION RUPEES
WINDLAS BIOTECH LTD MARCH-QUARTER CONSOL REVENUE FROM OPERATIONS 1.71 BILLION RUPEES VERSUS 1.41 BILLION RUPEES
Source text for Eikon: ID:nNSE8rxDRK
Further company coverage: WINL.NS
(([email protected];))
India's Windlas Biotech Sept-Qtr Consol Net Profit Rises
Nov 8 (Reuters) - Windlas Biotech Ltd WINL.NS:
INDIA'S WINDLAS BIOTECH SEPT-QUARTER CONSOL NET PROFIT 140.3 MILLION RUPEES VERSUS PROFIT 121.9 MILLION RUPEES
WINDLAS BIOTECH SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 1.53 BILLION RUPEES VERSUS 1.33 BILLION RUPEES
Source text for Eikon: ID:nNSE6v9KXg
Further company coverage: WINL.NS
(([email protected];;))
Nov 8 (Reuters) - Windlas Biotech Ltd WINL.NS:
INDIA'S WINDLAS BIOTECH SEPT-QUARTER CONSOL NET PROFIT 140.3 MILLION RUPEES VERSUS PROFIT 121.9 MILLION RUPEES
WINDLAS BIOTECH SEPT-QUARTER CONSOL REVENUE FROM OPERATIONS 1.53 BILLION RUPEES VERSUS 1.33 BILLION RUPEES
Source text for Eikon: ID:nNSE6v9KXg
Further company coverage: WINL.NS
(([email protected];;))
India's Windlas Biotech June-Quarter Consol Net Profit Rises
Aug 8 (Reuters) - Windlas Biotech Ltd WINL.NS:
JUNE-QUARTER CONSOL NET PROFIT 120.7 MILLION RUPEES VERSUS 98 MILLION RUPEES
JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 1.45 BILLION RUPEES VERSUS 1.2 BILLION RUPEES
Source text for Eikon: [ID:]
Further company coverage: WINL.NS
(([email protected];))
Aug 8 (Reuters) - Windlas Biotech Ltd WINL.NS:
JUNE-QUARTER CONSOL NET PROFIT 120.7 MILLION RUPEES VERSUS 98 MILLION RUPEES
JUNE-QUARTER CONSOL REVENUE FROM OPERATIONS 1.45 BILLION RUPEES VERSUS 1.2 BILLION RUPEES
Source text for Eikon: [ID:]
Further company coverage: WINL.NS
(([email protected];))
India's Windlas Biotech Mar-Quarter Consol Net Profit Falls
May 5 (Reuters) - Windlas Biotech Ltd WINL.NS:
INDIA'S WINDLAS BIOTECH MAR-QUARTER CONSOL NET PROFIT 114.4 MILLION RUPEES VERSUS 147.9 MILLION RUPEES
WINDLAS BIOTECH MAR-QUARTER CONSOL REVENUE FROM OPERATIONS 1.41 BILLION RUPEES VERSUS 1.22 BILLION RUPEES
INDIA'S WINDLAS BIOTECH LTD DIVIDEND OF 4 RUPEES PER SHARE
Source text for Eikon: [ID:]
Further company coverage: WINL.NS
(([email protected];))
May 5 (Reuters) - Windlas Biotech Ltd WINL.NS:
INDIA'S WINDLAS BIOTECH MAR-QUARTER CONSOL NET PROFIT 114.4 MILLION RUPEES VERSUS 147.9 MILLION RUPEES
WINDLAS BIOTECH MAR-QUARTER CONSOL REVENUE FROM OPERATIONS 1.41 BILLION RUPEES VERSUS 1.22 BILLION RUPEES
INDIA'S WINDLAS BIOTECH LTD DIVIDEND OF 4 RUPEES PER SHARE
Source text for Eikon: [ID:]
Further company coverage: WINL.NS
(([email protected];))
Events:
Dividend
Dividend
Dividend
More Small Cap Ideas
See similar 'Small' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Windlas Biotech do?
Windlas Biotech Limited is a leading pharmaceutical CDMO company in India, offering a wide range of development and manufacturing services of high-quality and cost-effective products globally, along with branded products in trade generics and OTC markets.
Who are the competitors of Windlas Biotech?
Windlas Biotech major competitors are Indoco Remedies, Vimta Labs, IOL Chem & Pharma, Senores Pharmaceutic, Solara Active Pharma, Bajaj Healthcare, Amrutanjan Healthcar. Market Cap of Windlas Biotech is ₹2,179 Crs. While the median market cap of its peers are ₹2,182 Crs.
Is Windlas Biotech financially stable compared to its competitors?
Windlas Biotech seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Windlas Biotech pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Windlas Biotech latest dividend payout ratio is 19.66% and 3yr average dividend payout ratio is 19.77%
How has Windlas Biotech allocated its funds?
Companies resources are allocated to majorly productive assets like Plant & Machinery and unproductive assets like Cash & Short Term Investments
How strong is Windlas Biotech balance sheet?
Balance sheet of Windlas Biotech is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Windlas Biotech improving?
Yes, profit is increasing. The profit of Windlas Biotech is ₹61.71 Crs for TTM, ₹58.19 Crs for Mar 2024 and ₹42.63 Crs for Mar 2023.
Is the debt of Windlas Biotech increasing or decreasing?
Yes, The debt of Windlas Biotech is increasing. Latest debt of Windlas Biotech is -₹16.29 Crs as of Sep-24. This is greater than Mar-24 when it was -₹61.76 Crs.
Is Windlas Biotech stock expensive?
Yes, Windlas Biotech is expensive. Latest PE of Windlas Biotech is 35.31, while 3 year average PE is 24.09. Also latest EV/EBITDA of Windlas Biotech is 23.88 while 3yr average is 13.01.
Has the share price of Windlas Biotech grown faster than its competition?
Windlas Biotech has given better returns compared to its competitors. Windlas Biotech has grown at ~57.94% over the last 3yrs while peers have grown at a median rate of -8.0%
Is the promoter bullish about Windlas Biotech?
Promoters seem not to be bullish about the company and have been selling shares in the open market. Latest quarter promoter holding in Windlas Biotech is 62.34% and last quarter promoter holding is 62.51%
Are mutual funds buying/selling Windlas Biotech?
The mutual fund holding of Windlas Biotech is decreasing. The current mutual fund holding in Windlas Biotech is 6.7% while previous quarter holding is 7.11%.